# Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

> **NCT03895970** · PHASE2 · COMPLETED · sponsor: **Peking Union Medical College Hospital** · enrollment: 32 (actual)

## Conditions studied

- Liver Neoplasm Malignant Primary
- Cholangiocarcinoma
- Combinational Immunotherapy
- Biomarker

## Interventions

- **DRUG:** Lenvatinib plus Pembrolizumab

## Key facts

- **NCT ID:** NCT03895970
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-20
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-08-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03895970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03895970, "Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03895970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*